Quality of Life and Sexual Health in the Aging of PCa Survivors
- PMID: 24744780
- PMCID: PMC3976934
- DOI: 10.1155/2014/470592
Quality of Life and Sexual Health in the Aging of PCa Survivors
Erratum in
-
Corrigendum to "Quality of Life and Sexual Health in the Aging of PCa Survivors".Int J Endocrinol. 2015;2015:675101. doi: 10.1155/2015/675101. Epub 2015 Feb 11. Int J Endocrinol. 2015. PMID: 25763069 Free PMC article.
Abstract
Prostate cancer (PCa) is the most common malignancy in elderly men. The progressive ageing of the world male population will further increase the need for tailored assessment and treatment of PCa patients. The determinant role of androgens and sexual hormones for PCa growth and progression has been established. However, several trials on androgens and PCa are recently focused on urinary continence, quality of life, and sexual function, suggesting a new point of view on the whole endocrinological aspect of PCa. During aging, metabolic syndrome, including diabetes, hypertension, dyslipidemia, and central obesity, can be associated with a chronic, low-grade inflammation of the prostate and with changes in the sex steroid pathways. These factors may affect both the carcinogenesis processes and treatment outcomes of PCa. Any treatment for PCa can have a long-lasting negative impact on quality of life and sexual health, which should be assessed by validated self-reported questionnaires. In particular, sexual health, urinary continence, and bowel function can be worsened after prostatectomy, radiotherapy, or hormone treatment, mostly in the elderly population. In the present review we summarized the current knowledge on the role of hormones, metabolic features, and primary treatments for PCa on the quality of life and sexual health of elderly Pca survivors.
Figures
References
-
- Sakr WA, Haas GP, Cassin BF, Pontes JE, Crissman JD. The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. Journal of Urology. 1993;150(2):379–385. - PubMed
-
- Guzzo TJ, Kutikov A, Canter DJ, et al. The clinical and pathological history of prostate cancer progression in men with a prior history of high grade prostatic intraepithelial neoplasia. The Canadian Journal of Urology. 2008;15(4):4174–4179. - PubMed
-
- Alva A, Hussain M. The changing natural history of metastatic prostate cancer. Cancer Journal. 2013;19(1):19–24. - PubMed
-
- Boyle P, Maisonneuve P, Napalkov P. Incidence of prostate cancer will double by the year 2030: the argument for. European Urology. 1996;29(2):3–9. - PubMed
-
- Grossmann M, Cheung AS, Zajac JD. Androgens and prostate cancer, pathogenesis and deprivation therapy. Best Practice and Research. Clinical Endocrinology and Metabolism. 2013;27(4):603–616. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
